Also found in: Medical.
a1PIHuman Alpha 1-Proteinase Inhibitor
References in periodicals archive ?
A1PI raises levels of AAT in the body and provides the lung with a protective shield against neutrophil elastase, the destructive enzyme.
6 million as well as expenses related to the expansion of the sales force and promotional activities related to the Gamunex IGIV CIDP indication in addition to Prolastin A1PI patient identification.
PROLASTIN (Alpha1-Proteinase Inhibitor [Human]) is derived from human plasma and is administered intravenously to raise the levels of A1PI in the blood and lungs.
This increase was largely due to accelerated vesting of stock compensation as well as increased sales and marketing expenses relating to expansion of the sales and marketing activities for the Gamunex IGIV CIDP indication and Prolastin A1PI patient identification.
In order to recover active pharmaceutical proteins, such as factor VIII, plasminogen, fibrinogen, immunoglobulin G, A1PI or albumin during the fractionation process, the proteins are isolated and purified in various steps.
A1PI is a treatment for the prevention of emphysema (hereditary deficiency) that was approved by the US Food and Drug Administration in July 2003 after a fast-track review.